| 000852 |
Peter C. Taylor ; Didier Saurigny [Royaume-Uni] ; Jiri Vencovsky [République tchèque] ; Tsutomu Takeuchi [Japon] ; Tadashi Nakamura [Japon] ; Galina Matsievskaia [Russie] ; Barbara Hunt [États-Unis] ; Thomas Wagner [Suisse] ; Bernard Souberbielle [Royaume-Uni] | Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial |
